Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

It wouldn’t make much sense to sack the fire service during a forest fire, yet that’s effectively what US President Donald Trump has done by suspending funding to the World Health Organization (WHO) in the middle of a pandemic. The WHO is by no means perfect, but undermining the world’s only global public health agency does not serve US interests.

The US is the biggest contributor to the 194-member WHO, providing around US$400 million (£322 million) annually, which makes up about a fifth of the budget. The organisation has been asked to do more with less for decades and is already in a fairly perilous financial situation.

Although the move is characteristically shortsighted, this time Trump’s decision was premeditated. On April 10, he hinted that US funding would be withdrawn, adding: “We’re looking at it very, very closely … we’ll have a lot to say about it.”

The following week he confirmed the suspension of funding and blamed the WHO for “severely mismanaging and covering up the spread of coronavirus”. He argued that the organisation had been too slow to investigate the outbreak and had been complicit in China’s suppression and misreporting of cases.

Read the full article on The Conversation website, written by Luke Allen, GP Academic Clinical Fellow in Nuffield Department of Primary Care Health Sciences

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Major grant to strengthen research and benefit patients

Oxford University Hospitals (OUH) has made a grant of £11.5 million to the University of Oxford, which the University will match with other funding, to allow the development of major clinical research facilities which have the potential to support the introduction of innovative and ground-breaking treatments for patients.

Dr Lennard Lee awarded ACP McElwain Prize for contributions to medical oncology

Dr Lee (Department of Oncology) received the award to acknowledge his contributions during the COVID-19 pandemic, through the establishment of the UK Coronavirus Cancer Monitoring Project.

Oxford joins forces with 11 universities to launch social impact investment fund

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

Ivermectin to be investigated as a possible treatment for COVID-19 in the PRINCIPLE trial

From today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.